Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.

Casella J. F. , Barton B. A. , Kanter J., Black L. V. , Majumdar S., Inati A., ...More

JAMA, vol.325, pp.1513-1523, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 325
  • Publication Date: 2021
  • Doi Number: 10.1001/jama.2021.3414
  • Journal Name: JAMA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, Gender Studies Database, Index Islamicus, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Psycinfo, Public Affairs Index, Veterinary Science Database, DIALNET
  • Page Numbers: pp.1513-1523
  • Istanbul University Affiliated: Yes


Key PointsQuestionCan poloxamer 188, an agent that is reported to reduce blood viscosity and cell-cell interactions, effectively reduce the duration of vaso-occlusive episodes (painful crises) in hospitalized patients with sickle cell disease? FindingsIn this randomized clinical trial that included 388 children and adults with sickle cell disease, treatment with poloxamer 188 vs placebo resulted in mean time to last dose of parenteral opioids during vaso-occlusive episodes of 81.8 vs 77.8 hours, a difference that was not statistically significant. MeaningAmong patients with sickle cell disease, poloxamer 188 did not significantly shorten the duration of painful vaso-occlusive episodes.